tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

CH:NWRN Stock Latest News

Newron Raises Up to EUR 38 Million to Advance Phase III Schizophrenia Drug Evenamide
Company AnnouncementsNewron Raises Up to EUR 38 Million to Advance Phase III Schizophrenia Drug Evenamide
7d ago
Newron Raises Up to EUR 38 Million to Advance Phase III Schizophrenia Drug
PremiumCompany Announcements
Newron Raises Up to EUR 38 Million to Advance Phase III Schizophrenia Drug
7d ago
Newron’s Evenamide Shows Durable Benefits as Add-On Therapy in Treatment-Resistant Schizophrenia
PremiumCompany Announcements
Newron’s Evenamide Shows Durable Benefits as Add-On Therapy in Treatment-Resistant Schizophrenia
21d ago
Newron Pharma price target raised to CHF 43 from CHF 26 at H.C. Wainwright
PremiumThe Fly
Newron Pharma price target raised to CHF 43 from CHF 26 at H.C. Wainwright
1M ago
PremiumCompany Announcements
EA Pharma Starts Phase III Trial of Newron’s Evenamide for Treatment‑Resistant Schizophrenia in Japan
2M ago
PremiumCompany AnnouncementsNewron Secures EU Patent Extension for Lead Schizophrenia Drug Evenamide
2M ago
Premium
Company Announcements
Newron Wins Long-Term EU Patent Protection for Lead Schizophrenia Drug Evenamide
2M ago
Newron Pharma initiated with a Buy at Lucid Capital
Premium
The Fly
Newron Pharma initiated with a Buy at Lucid Capital
2M ago
Newron Pharmaceuticals’ Evenamide Advances with ENIGMA-TRS 2 Trial: Analyst Reiterates Buy Rating
PremiumRatings
Newron Pharmaceuticals’ Evenamide Advances with ENIGMA-TRS 2 Trial: Analyst Reiterates Buy Rating
2M ago
Newron Pharma initiated with a Buy at H.C. Wainwright
PremiumThe Fly
Newron Pharma initiated with a Buy at H.C. Wainwright
3M ago
Newron Pharmaceuticals Launches Phase III Study for Schizophrenia Treatment
PremiumCompany Announcements
Newron Pharmaceuticals Launches Phase III Study for Schizophrenia Treatment
3M ago
Newron Pharmaceuticals Advances Evenamide for Schizophrenia Treatment
PremiumCompany Announcements
Newron Pharmaceuticals Advances Evenamide for Schizophrenia Treatment
5M ago
Newron Pharmaceuticals Advances Evenamide Development with Positive H1 2025 Results
PremiumCompany AnnouncementsNewron Pharmaceuticals Advances Evenamide Development with Positive H1 2025 Results
5M ago
Newron Pharmaceuticals Advances Evenamide Phase III Trials for Schizophrenia
Premium
Company Announcements
Newron Pharmaceuticals Advances Evenamide Phase III Trials for Schizophrenia
5M ago
Newron Pharmaceuticals Advances Evenamide for Schizophrenia Treatment
Premium
Company Announcements
Newron Pharmaceuticals Advances Evenamide for Schizophrenia Treatment
6M ago
Newron Pharmaceuticals Launches Phase III Study for Schizophrenia Treatment
PremiumCompany Announcements
Newron Pharmaceuticals Launches Phase III Study for Schizophrenia Treatment
7M ago
Newron Pharmaceuticals Unveils Promising Schizophrenia Treatment Findings
PremiumCompany Announcements
Newron Pharmaceuticals Unveils Promising Schizophrenia Treatment Findings
7M ago
Newron Pharmaceuticals Advances Phase III Program for Schizophrenia Treatment
PremiumCompany Announcements
Newron Pharmaceuticals Advances Phase III Program for Schizophrenia Treatment
10M ago
Newron Pharmaceuticals Advances Phase-III Trials for Schizophrenia Treatment
PremiumCompany Announcements
Newron Pharmaceuticals Advances Phase-III Trials for Schizophrenia Treatment
10M ago
New Leadership and Strategic Financial Moves at Newron Pharmaceuticals
PremiumCompany AnnouncementsNew Leadership and Strategic Financial Moves at Newron Pharmaceuticals
10M ago
Newron Pharmaceuticals Reports Strong 2024 Results and Strategic Growth Plans for 2025
Premium
Company Announcements
Newron Pharmaceuticals Reports Strong 2024 Results and Strategic Growth Plans for 2025
11M ago
Newron Pharmaceuticals Reports Profit and Strategic Advances in 2024
Premium
Company Announcements
Newron Pharmaceuticals Reports Profit and Strategic Advances in 2024
11M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >